Analysts have clear opinions on NERV.
There are 3 analysts on the Wall offering 12 month price targets for Minerva Neurosciences in the last 3 months. The average price target is $18.33 with a high forecast of $20.00 and a low forecast of $17.00. The average price target represents a increase from the last price of .
Minerva Neurosciences, Inc. (NERV) is followed by 3 analysts on the street.
Douglas Tsao from H.C. Wainwright rates it a Buy with a target of $20.00.
Similarly, Last month Joel Beatty of Citigroup Reiterated a Buy with a target of $18.00.
The consensus on the street is Strong Buy.
What does Minerva Neurosciences, Inc.(NERV) do ?
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.
Minerva Neurosciences, Inc. (NERV) Insider Trades
Multiple company employees have indulged in significant insider trading. Minerva Neurosciences, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):
EVP, CFO, CBO, Race Geoff : S – Sale+OE(-$41,365) of NERV in the trading session of 2019-12-17.
CEO Luthringer Remy : S – Sale+OE(-$17,125) of NERV in the trading session of 2019-12-17.
SVP, Chief Accounting Officer Ahlholm Frederick W : S – Sale+OE(-$11,055) of Minerva Neurosciences, Inc. in the trading session of 2019-12-17.
Looking for stocks just like NERV?
Based on Wall Street analyst research, several stocks are similar to NERV
– JNJ [Info can be found here: https://www.nasdaq.com/market-activity/stocks/JNJ ]
– ACAD [Info can be found here: https://www.nasdaq.com/market-activity/stocks/ACAD ]
– BMY [Info can be found here: https://www.nasdaq.com/market-activity/stocks/BMY ]